Compass Therapeutics director Brett Kaplan resigns from Board effective Feb 25, 2022

Compass Therapeutics, Inc.

Brett Kaplan, M.D. resigned from the Board and all committees, effective February 25, 2022.
Resignation was not due to any disagreement with the Company's operations, policies, or practices.
No replacement announced; Board composition changes.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Brett Kaplan

director

CMPX · Compass Therapeutics, Inc.

Effective: 2022-02-25
Filed: February 25, 2022, 6:59 PM ET

On February 22, 2022, Brett Kaplan, M.D., a member of the Board of Directors (the “Board”) of Compass Therapeutics, Inc. (the “Company”), notified the Company of his resignation from the Board and all committees thereof, effective February 25, 2022.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Brett Kaplan resigned as director at Compass Therapeutics, Inc..

Action: resigned
Role: director

Exact text from the filing

On February 22, 2022, Brett Kaplan, M.D., a member of the Board of Directors (the “Board”) of Compass Therapeutics, Inc. (the “Company”), notified the Company of his resignation from the Board and all committees thereof, effective February 25, 2022.

View on SEC.gov

Compass Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-054600

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.